Justeau et al. demonstrated that in advanced NSCLC patients with PD-L1 expression ≥50% treated with first-line pembrolizumab, the KRAS G12C mutation group (n = 86) and the KRAS non-G12C mutation group (n = 141) showed no significant difference in ORR (47% vs. 40%), PFS (7 vs. 4.8 months), and OS (18.4 vs. 20.6 months).22 A retrospective study by Arbour et al. showed that in NSCLC receiving first-line immunotherapy, patients with the KRAS G12C mutation (n = 352) had comparable PFS (3.7 vs. 3.3 months, p = .89) to the non-G12C mutation group (n = 418).49 Here, KRAS is linked to non-small cell lung carcinoma.